六味地黄丸联合西药可提高治疗2型糖尿病的疗效：一项随机对照试验的荟萃分析

Objective: To perform meta-analyses evaluating the ef?cacy of adding Liuwei Dihuang Pills (六味地黄丸, LDP) to Western medicine in improving treatment outcomes for type 2 diabetes. Methods: Medline, PubMed, Cochrane Library, and Chinese databases, including the Chinese National Knowledge Infrastructure were searched to identify eligible studies; i.e., if the study involved a randomized clinical trial in which the experimental group combined LDP with Western drugs and the control group used the corresponding Western drugs alone to treat type 2 diabetes. Outcomes were measured in terms of fasting blood glucose (FBG), postprandial blood glucose (2hPG) and HbA1c level. Efficacy was also measured by using control and response rates. The combined odds ratio (OR), mean difference (MD), and 95% con?dence intervals (95% CI) were calculated. Results: Studies included in the analysis were less adequate than expected in terms of methodological quality. A total of 1,609 patients from 18 studies were included. We found that adding LDP can lower patients'' FBG (MD=0.54 mmol/L, 95% CI [0.15, 0.93], P=0.007), 2hPG (MD=1.05 mmol/L, 95% CI [0.29, 1.81], P<0.01) and HbA1c (MD=0.23, 95% CI [0.02, 0.45], P=0.008). There were also improvements in treatment response rates (OR=3.41, 95% CI [2.38, 4.90], P<0.01) and control rates (OR=2.47, 95% CI [1.91, 3.20], P<0.01). Conclusion: Adding LDP to Western medicine might improve treatment outcomes of diabetes, including FBG, 2hPG, response rates and control rates.     

Comprehensive Treatment with Chinese Medicine in Patients with Advanced Non-Small Cell Lung Cancer: A Multicenter, Prospective, Cohort Study

Objective: To determine whether additional Chinese medicine(CM) could prolong survival and improve the quality of life(QOL) in patients with advanced non-small cell lung cancer(NSCLC) compared with Western medicine(WM) alone. Methods: This was a multicenter, prospective cohort study. A total of 474 hospitalized patients with stage Ⅲ–Ⅳ NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy, chemotherapy, and optimal supportive therapy according to the National Comprehensive Cancer Network(NCCN) guidelines. In the integrative medicine(IM) group, individualized CM(Chinese patent medicines and injections) and WM were administered. The primary end point was overall survival, and the secondary end points were time to disease progression, adverse events, and QOL. Follow-up clinical examinations and chest radiography were performed every 2 months. Results: The median survival was 16.60 months in the IM group and 13.13 months in the WM group(P0.01). The incidences of loss of appetite, nausea, and vomiting in the IM group were significantly lower than those in the WM group(P0.05). The QOL based on Functional Assessment of Cancer Therapy-Lung in the IM group was markedly higher than that in the WM group at the fourth course(P0.05). Conclusions: Additional CM may prolong survival and improve the QOL patients with NSCLC. The adverse effects of radio-and chemotherapy may be attenuated as CM is used in combination with conventional treatments.     

中西医结合治疗缺血性脑卒中的成本效益分析

Objective:To evaluate the cost-effectiveness of combining Chinese medicine(CM)with Western medicine(WM)for ischemic stroke patients.Methods:Hospitalization summary reports between 2006 and 2010from eight hospitals in Beijing were used to analyze the length of stay(LOS),cost per stay(CPS),and outcomes at discharge.Results:Among 12,009 patients(female,36.44%;mean age,69.98±13.06 years old),a substantial number of patients were treated by the WM_Chinese patent medicine(CPM)_Chinese herbal medicine(CHM)(38.90%);followed by the WM_CPM(32.55%),the WM(24.26%),and the WM_CHM(4.15%).With adjustment for confounding variables,LOS of the WM_CPM_CHM group was about 10 days longer than that of the WM group,and about 6 days longer than that of the WM_CPM group or the WM_CHM group(P0.01);CPS of the WM_CPM_CHM group was United States dollar(USD)1,288 more than that of the WM group,and about USD600 more than that of the WM_CPM group or the WM_CHM group(P0.01).Compared with the WM group,odd ratio(OR)of recovered and improved outcome of the WM_CPM_CHM group was the highest[OR:12.76,95%confidence intervals(CI):9.23,17.64,P0.01],OR of death outcome of the WM_CPM_CHM group was the lowest(OR:0.08,95%CI:0.05,0.12,P0.01).There was no significant difference between LOS,CPS and OR of the WM_CPM group and those of the WM_CHM group(P0.05).Cost/effectiveness and incremental costeffectiveness ratio of the WM_CPM_CHM group were robustly higher than those of the WM group.Conclusion:Compared with WM alone,supplementing CPM and CHM to WM provides significant health benefits of improving the chance of recovered and improved outcome,and reducing the death rate,at an expense of longer LOS and higher CPS.     

基于中医三型辨证治疗2型糖尿病的系统综述

Objective： To evaluate the efficacy and safety of ＂Three-Typed Syndrome Differentiation＂ （I-TSD） in treating type 2 diabetes mellitus patients. Methods： A systematic review and meta-analysis was done based on the clinical diabetes treatment literature of the ＂I-I＇SD＂. Overseas databases like the PubMed/MEDLINE, EMBASE, Cochrane Library and Cochrane Central Register of Controlled Clinical Trials, and China databases like China Biology Medicine Disc （CBM）, Chinese national Knowledge Infrastructure （CNKI）, Wanfang database, and VIP database, without limitation on language, were included with the time limitation from Jan 1982 to Dec 2012 by retrieval of relative original clinical research articles. Results： Nineteen articles where contains 1,840 diabetes patients were obtained, in which no adverse reactions were reported. Of these, 14 literatures involved the effect of fasting blood glucose （FBG）, 10 involved that of postprandial 2-h blood glucose （P2hBG）, and 19 involved the overall efficacy based on the national Chinese medicine （CM） diagnosis and treatment standard of diabetes. All the meta-analysis results prefer to the ＂TTSD＂ groups （CM＋Westem medicine Based on I-I＇SD）. The results show that, beside the efficacy of Westem medicine, the concentrations of FBG and P2hBG in ＂TTSD＂ groups continue to drop with statistical significance. For ＂TTSD＂ groups, the FBG subsequently dropped 1.03 mmol/L, 95%CI [1.24,0.82] （P〈0.00001）, the P2hBG subsequently dropped 1.09 mmol/L, 95% CI [1.61, 0.57] （P〈0.0001）, and the overall efficacies benefit 3.46 times those of Western medicine alone, 95% CI [2.67,4.48] （P〈0.00001）. Conclusions： The CM by the diagnosis and treatment of type 2 diabetes based on ＂TTSD might be safe and effective, and could better improve both blood glucose and the overall status of patients, including symptoms.     

Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?

Objective:To assess the efficacy of Chinese medicine(CM) on patients with pancreatic cancer(PC) in a retrospective population-based study.Methods:Between January 1,2013,and August 30,2016,according to whether received Western medicine treatment,the patients were included into either integrative medicine(IM) group or CM group.All enrolled patients were orally administrated with Gexia Zhuyu Decoction(膈下逐瘀汤) or Liujun Ermu Decoction(六君二母汤) by syndrome differentiation,twice a day,last for at least 2 months.The primary end point was overall survival(OS).Results:A total of 174 patients with PC were enrolled in this study.In stage Ⅰ/Ⅱ,the median OS was 20.5 months in the IM group [95% confidence interval(CI),12.499 to 28.501] and 11.17 months in the CM group(95% CI,5.160 to 17.180,P=0.015).The 1-and 2-year survival rates for the two groups were 47.0%,40.0% and 21.0%,21.0%,respectively.In stage Ⅲ/Ⅳ,median OS was 13.53 months(95% CI,8.665 to 18.395) in the IM group versus 6.4 months(95% CI,0.00 to 15.682) in the CM group,respectively(P=0.32).The 1-and 2-year survival rate for the IM and CM groups were 27.0%,7.0% and 20.0%,2.0%,respectively.Conclusions:Intervention of CM contributes to the different survival benefits for PC in different stages.Multimodality treatment might be a promising strategy for PC patients in early stage.While,in advanced stage,CM might be an alternative candidate for PC patients.     

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Objective:To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive 1-125 seeds interstitial implantation(ISI) synchronized chemotherapy and Chinese medicine(CM) for the treatment of advanced stage of non-small cell lung cancer(NSCLC).Methods:Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups:the synchronized therapy group(A),the chemotherapy plus CM-treated group(B),and the chemotherapy-treated group(C);a 2-month course of treatment was administered to them all.The effectiveness of treatment was evaluated based on tumor size,tumor markers(carcinoembryonic,squamous cell carcinoma-associated antigen,and cytokeratin 19 fragment),clinical symptoms,and quality of life(QOL) in patients.Results:The total effective rates of Groups A to C were 83.33%,46.67%,and 43.33%,respectively.The tumor markers were reduced obviously in Group A,showing significant difference compared with those in the other two groups.Additionally,QOL was elevated and cancer-related symptoms were alleviated more significant in Group A than those in Group C(all P<0.05). Conclusion:The synchronized therapy of 1-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.     

Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine

Objective: To investigate the efficacy of integrated Chinese and Western medicine(IM) in the treatment of metastatic colorectal cancer(m CRC) in a cohort study.Methods: The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone.The study design was adopted with "continuous administration of Chinese medicine for 3 months" as the exposure factor.Patients who met this exposure factor were assigned to the IM cohort(Group A,110 patients).Patients who did not meet this exposure factor were assigned to the Western medicine cohort(Group B,225 patients).The overall survival(OS),progression-free survival(PFS),and 1 st year,2 nd year,and 3 rd year survival in the two cohorts were compared.Results: The median OS in Group A and B were 18 months [95% confidence interval(CI) 15–21] and 16 months(95% CI 14–18),respectively,and the median PFS in Group A and B were 6 months(95% CI 4–7) and 5 months(95% CI 4–6),respectively.No statistically significant differences were observed between the groups(P=0.186,P=0.223).Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups: female patients,patients with lesions in the right half of the colon,and those who received first-line treatment(P0.05).In the subgroup of elderly patients(age65 years),the OS in Group A was longer than that in Group B(P0.05).Conclusion: IM could prolong the survival of patients with m CRC.(Registry No.Chi CTR-IOR-17010497)     

Quality Assessment of Clinical Practice Guidelines for Integrative Medicine in China: A Systematic Review

Objective: To assess the quality of integrative medicine clinical practice guidelines(CPGs) published before 2014. Methods: A systematic search of the scientific literature published before 2014 was conducted to select integrative medicine CPGs. Four major Chinese integrated databases and one guideline database were searched: the Chinese Biomedical Literature Database(CBM), the China National Knowledge Infrastructure(CNKI), China Science and Technology Journal Database(VIP), Wanfang Data, and the China Guideline Clearinghouse(CGC). Four reviewers independently assessed the quality of the included guidelines using the Appraisal of Guidelines for Research and Evaluation(AGREE) Ⅱ Instrument. Overall consensus among the reviewers was assessed using the intra-class correlation coefficient(ICC). Results: A total of 41 guidelines published from 2003 to 2014 were included. The overall consensus among the reviewers was good [ICC: 0.928; 95% confidence interval(CI): 0.920 to 0.935]. The scores on the 6 AGREE domains were: 17% for scope and purpose(range: 6% to 32%), 11% for stakeholder involvement(range: 0 to 24%), 10% for rigor of development(range: 3% to 22%), 39% for clarity and presentation(range: 25% to 64%), 11% for applicability(range: 4% to 24%), and 1% for editorial independence(range: 0 to 15%). Conclusions: The quality of integrative medicine CPGs was low, the development of integrative medicine CPGs should be guided by systematic methodology. More emphasis should be placed on multi-disciplinary guideline development groups, quality of evidence, management of funding and conflicts of interest, and guideline updates in the process of developing integrative medicine CPGs in China.     

Clinical Efficacy of Traditional Chinese Medicine on Acute Myocardial Infarction——A Prospective Cohort Study

<正>Objective:To evaluate the clinical effects of Chinese medicine(CM) on acute myocardial infarction (AMI) with a prospective cohort study.Methods:A total of 334 AMI patients from January 2007 to March 2009 were consecutively enrolled,and were assigned to a treatment group(169 cases) treated with combined therapy(CM for at least one month and Western medicine) and a control group(165 cases) with Western medicine alone.Clinical data including age,gender,smoking,medical history,infarction area,heart functional classification,CM syndrome scores,blood-stasis syndrome score,primary end-point(death,nonfatal myocardial infarction,and revascularization) and secondary end-point(ischemic stroke,rehospitalization due to angina,heart failure and shock),were collected. CM syndrome scores,blood-stasis syndrome score,primary end-point and secondary end-point were collected during the 6-month follow-up.Kaplan-Meier method was used for the survival analysis.The multifactor analysis was analyzed by Cox proportional hazards regression.Results:At the end of 6-month the CM syndrome score and blood- stasis syndrome score in the treatment group were lower than those in the control group(P0.01),especially the symptoms of chest pain,spontaneous perspiration and insomnia.Rehospitalization rate due to angina during the 6-month follow-up in the treatment group(2.96%) was lower than that in the control group(7.88%,P0.05).Kaplan- Meier survival curve showed that event-free cumulated survival of rehospitalization due to angina during the 6-month follow-up in the treatment group was higher than that in the control group(Log rank 4.700,P=0.03).Cox regression analysis showed that heart dysfunction[hazard ratio(HR)=1.601,95%CI=1.084-2.364,P=0.018]and diabetes mellitus(HR=1.755,95%Cl=1.031-2.989,P=0.038) were hazard factors to end-point,whereas CM(HR 0.405,95% Cl=0.231-0.712,P=0.002),percutaneous coronary intervention(PCI,HR=0.352,95%CI=0.204-0.607,P0.001) and angiotensin converting enzyme(ACE) inhibitors(HR=0.541,95%Cl=0.313-0.936,P=0.028) were protective factors.Conclusions:CM therapy could decrease CM syndrome scores and blood-stasis syndrome score,reduce the rehospitalization rate during 6-month follow-up due to angina.Heart dysfunction and diabetes mellitus were hazard factors to end-point,whereas CM,PCI and ACE inhibitors were protective factors.     

Sodium Tanshinone ⅡA Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials

Objective: To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection(STS) as one adjuvant therapy for treating unstable angina pectoris(UAP). Methods: Randomized controlled trials(RCTs) of UAP treated by STS were searched in the China National Knowledge Infrastructure Database(CNKI), VIP Database for Chinese Technical Periodicals(VIP), Wanfang Database, the Chinese Biomedical Literature Database(CBM), Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results: The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine(WM) in the treatment of UAP can obviously improve the total effective rate [risk ratio(RR)=1.31, 95% confidence interval(CI)(1.24,1.39), P0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI(1.30,1.56), P0.0001], decrease the level of CRP [mean difference(MD)=–3.06, 95%CI(–3.85, –2.27), P0.00001], fibrinogen [MD=–1.03, 95% CI(–1.16, –0.89), P0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI(–0.92, –0.49), P0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI(1.28, 9.94), P0.05]. Conclusions: Compared with WM, the combined use of STS was more effective.     

Ginkgo Leaf Extract and Dipyridamole Injection as Adjuvant Treatment for Angina Pectoris: A Meta-Analysis of 41 Randomized Controlled Trials

Objective: To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection(GD) as one adjuvant therapy for treating angina pectoris(AP) and to evaluate the relevant randomized controlled trials(RCTs) with meta-analysis. Methods: RCTs concerning AP treated by GD were searched in China Biology Medicine Disc(SinoMed), PubMed, the China National Knowledge Infrastructure Database(CNKI), the Chinese Scientific Journals Database(VIP), Wanfang Database, Embase, and the Cochrane Library, from inception to February, 2017. The Cochrane Risk Assessment Tool was adopted to assess the methodological quality of the RCTs. The Review Manager 5.3 software was utilized to conduct the meta-analysis. Results: A total of 41 RCTs involving 4,462 patients were included in the meta-analysis. The results indicated that the combined use of GD and Western medicine(WM) against AP was associated with a higher total effective rate [risk ratio(RR)=1.25, 95% confidence interval(CI): 1.21–1.29, P0.01], total effective rate of electrocardiogram(RR=1.29, 95% CI: 1.21–1.36, P0.01). Additional, GD combined with WM could decrease the level of plasma viscosity [mean difference(MD)=–0.56, 95% CI: –0,81 to –0.30, P0.01], fibrinogen [MD=–1.02, 95% CI: –1.50 to –0.54, P0.01], whole blood low shear viscosity [MD=–2.27, 95% CI: –3.04 to –1.49, P0.01], and whole blood high shear viscosity(MD=–0.90, 95% CI: 1.37 to –0.44, P0.01). Conclusions: Comparing with receiving WM only, the combine use of GD and WM was associated with a better curative effect for patients with AP. Nevertheless, limited by the methodological quality of included RCTs more large-sample, multi-center RCTs were needed to confirm our findings and provide further evidence for the clinical utility of GD.     

Chinese Medicine for Idiopathic Parkinson's Disease: A Meta Analysis of Randomized Controlled Trials

Objective:To evaluate the efficacy of Chinese medicine(CM) adjunct to conventional medications for idiopathic Parkinson's disease(PD).Methods:Electronic English and Chinese databases including PubMed,Cochrane Library,Web of Science,Chinese Medical Current Contents,China National Knowledge Infrastructure,China Science and Technology Journal Database,Wanfang Med Database,and Traditional Chinese Medical Database System were used for key words searching in a highly sensitive search strategy.The extracted data was analyzed by the Review Manager 5.0.Results:Twelve trials involving 869 participants were included in the meta-analysis.Unified PD Rating Scale(UPDRS) I,Ⅱ,Ⅲ,Ⅳ scores and UPDRS Ⅰ-Ⅳ total scores were used to be the primary outcomes,Parkinson Disease Question-39(PDQ-39) and Scores of Chinese Medical Symptoms were the secondary outcomes.CM adjunct therapy had greater improvement in UPDRS Ⅰ[2 trials;standardized mean difference(SMD)-0.40,95%confidence interval(CI)-0.71 to-0.09;Z=2.49(P=0.01)],Ⅱ[5 trials;SMD-0.47,95%CI-0.69 to-0.25;Z=4.20(P0.01)],Ⅲ[5 trials;SMD-0.35,95%CI-0.57 to-0.13;Z=3.16(P=0.002)],Ⅳ scores[3 trials;SMD-0.32,95%CI-0.60 to-0.03;Z=2.17(P=0.03)],UPDRS Ⅰ-Ⅳ total scores[7 trials;SMD-0.36,95%CI-0.53 to-0.20;Z=4.24(P0.05)].PDQ-39 and Chinese medical symptoms compared to the conventional medication only.Conclusion:CM adjunct therapy has potential therapeutic benefits by decreasing UPDRS scores and reducing adverse effect.     

Effect of traditional and integrative regimens on quality of life and early renal impairment in elderly patients with isolated systolic hypertension

Objective：To observe the effect of Chinese medical regimen and integrative medical regimen on quality of life and early renal impairment in elderly patients with isolated systolic hypertension（EISH）.Methods： A multi-center,randomized,double-blinded controlled trail was adopted.A total of 270 cases of EISH were randomly divided into 3 groups：Chinese medicine group（CM）,combination group and Western medicine group （WM）.The course of treatment was 4 weeks.The clinical blood pressure,integral of quality of life（SF-36 scale）, immunoglubin G（IgG）,microalbumin（mALB）,β_2-microglobulin（β_2-MG）,transferrin（TRF）and N-acetyl-β＇- D-glucosa-minidase（NAG）in urine were determined before and after the treatment.Results：After treatment, systolic blood pressure depressed significantly in each group（P〈0.05）,and the combination group was superior to CM or WM group in depressing SBP（P〈0.05）; in each group,integral of quality of life improved in different degree,and combination group was superior to WM group in all 8 dimensions（P〈0.05）.The level of mALB andβ_2-MG in urine decreased in all groups（P〈0.05）,and the combination group was superior to CM group or WM group in decreasing mALB（P〈0.05）.Conclusions：Chinese medical regimen has affirmative effect in treating EISH patients,and could lower the systolic blood pressure,improve quality of life and early renal impairment of the patients,and integrative medical regimen has superiority on account of cooperation,and deserves further study.     

癌症疼痛病人伴随阿片类药物导致便秘的中医汤剂标准化治疗：一项多中心前瞻性随机对照试验

Objective： To observe the efficacy and the influence on quality of life （QOL） of syndrome differentiation treatment with Chinese medicine （CM） for opioid-induced constipation as well as the safety and influence on analgesic effect of opioids. Methods： Totally 406 cases enrolled from 53 collaborating medical centers were randomly assigned to a CM group and a control group. The CM group were treated with CM decoction based on syndrome differentiation, and the control group were treated with Phenolphthalein Tablet. Both groups were treated for 14 days. Cleveland constipation score （CCS）, numedcal rating scale （NRS） of pain and Chinese version of European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire-C30 V3.0 （EORTC QLQ-C30 V3.0） were used to evaluate the efficacy, pain controlled and QOL status. Results： The comparisons of CCS score reduction and QOL between the two groups after treatment suggested that the improvements of constipation and QOL in the CM group were better than that in the control group （P〈0.05）. The total efficiency of the CM group was better than the control group （93.5% vs. 86.4%, P〈0.05）. There was no significant difference in NRS scores between before and after treatment in both groups. There was no serious drug-related adverse event during the course of study. Conclusion： CM decoction could effectively treat opioid-induced constipation and improve patients＇ QOL at the same time. It is safe and doesnt affect the analgesic effect of opioids when treating constipation.     

Chinese Medicine Improves Postoperative Quality of Life in Endometriosis Patients: A Randomized Controlled Trial

Objective:To investigate the effect of Chinese medicine(CM) and Western medicine(WM) on quality of life(QOL) after conservative surgery for endometriosis.Methods:A total of 320 patients with endometriosis were randomized into two groups by using random block design,CM group(160 cases,activating blood circulation and removing blood stasis treatment based on syndrome differentiation) and WM group(160 cases,gonadotropin-releasing hormone agonist or gestrinone treatment) after conservative surgery.Treatment was given for 3-6 months(according to the revised American Fertility Society scoring system stage),and the World Health Organization QOL-BREF(WHOQOL-BREF) was applied to patients before and after treatment to assess QOL.Results:There were 136 cases in the CM group and 141 cases in the WM group completing therapy.In the CM group,the use of the WHOQOL-BREF showed that the physical,psychological and environmental scores post- treatment were significantly higher than those at pre-treatment(P<0.05),and for 12 items(pain and discomfort, energy and fatigue,sleep and rest,mobility,activities of daily living,work capacity,negative feelings,health and social care:accessibility and quality,participation in and opportunities for recreation/leisure activities,appetite, QOL score,overall health status and QOL),the difference in scores was significant(P<0.05).In the WM group,4 items(pain and discomfort,opportunities for acquiring new information and skills,QOL score,overall health status and QOL) had significantly different scores post-treatment compared with those at pre-treatment(P<0.05).Before treatment,the QOL in the two groups of patients showed no significant difference(P>0.05).After treatment,the scores for physical health in the CM group were significantly higher than those of the WM group(P<0.05) and the scores of 4 items(mobility,activities of daily living,sexual activity,QOL score) in the CM group were significantly higher than those in the WM group(P<0.05).Conclusions:CM and WM treatment could improve the QOL of patients with endometriosis after conservative surgery.CM treatment is more effective than WM.     

Gefitinib plus Fuzheng Kang'ai Formula(扶正抗癌方) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation:A Randomized Controlled Trial

Objective: To evaluate the effect of Fuzheng Kang'ai Formula(扶正抗癌方, FZKA) plus gefitinib in patients with advanced non-small cell lung cancer with epidermal growth factor receptor(EGFR) mutations. Methods: A randomized controlled trial was conducted from 2009 to 2012 in South China. Seventy chemotherapynaive patients diagnosed with stage ⅢB/Ⅳ non-small cell lung cancer with EGFR mutations were randomly assigned to GF group [gefitinib(250 mg/day orally) plus FZKA(250 m L, twice per day, orally); 35 cases] or G group(gefitinib 250 mg/day orally; 35 cases) according to the random number table and received treatment until progression of the disease, or development of unacceptable toxicities. The primary endpoint [progression-free survival(PFS)] and secondary endpoints [median survival time(MST), objective response rate(ORR), disease control rate(DCR) and safety] were observed. Results: No patient was excluded after randomization. GF group had significantly longer PFS and MST compared with the G group, with median PFS of 12.5 months(95% CI 3.30–21.69) vs. 8.4 months(95% CI 6.30–10.50; log-rank P0.01), MST of 21.5 months(95% CI 17.28–25.73) vs. 18.3 months(95% CI 17.97–18.63; log-rank P0.01). ORR and DCR in GF group and G group were 65.7% vs. 57.1%, 94.3% vs. 80.0%, respectively(P0.05). The most common toxic effects in the GF group and G group were rash or acne(42.8% vs. 57.1%, P0.05), diarrhea(11.5% vs. 31.4%, P0.05), and stomatitis(2.9% vs. 8.7%, P0.05). Conclusion: Patients with advanced non-small cell lung cancer selected by EGFR mutations have longer PFS, MST with less toxicity treated with gefitinib plus FZKA than gefitinib alone.     

Association of Platelet-Activating Factor Receptor Gene rs5938 (G/T) and rs313152 (T/C) Polymorphisms with Coronary Heart Disease and Blood Stasis Syndrome in A Chinese Han Population

Objective

To explore the association of the platelet-activating factor receptor (PAFR) gene rs5938, rs313152 and rs76744145 polymorphisms with coronary heart disease (CHD) and blood stasis syndrome (BSS) of CHD in Chinese Han population.

Methods

A total of 570 CHD patients (299 with BSS and 271 with non-BSS) and 317 controls were enrolled. The PAFR gene rs5938, rs313152 and rs76744145 polymorphisms were genotyped using the multiplex SNaPshot technology. The statistical analysis was conducted using a multiple variable logistic regression model.

Results

Significant differences were detected in the genotypes frequency distributions of the rs5938 (P<0.01), but not the rs313152 (P>0.05), between the controls and CHD patients. Individuals with an rs5938 or rs313152 mutated allele had a low risk for CHD [adjusted odds ratio (aOR)=0.35, 95% confidence interval (CI): 0.23 to 0.56, P<0.01; aOR=0.65, 95% CI: 0.46 to 0.91, P<0.05, respectively]. After the CHD patients were stratified as BSS or non-BSS according to their Chinese medicine patterns, the rs5938 polymorphism mutated alleles had a significant association with a low risk for BSS of CHD (aOR=0.32, 95% CI: 0.18 to 0.57, P<0.01) and non-BSS of CHD (aOR=0.31, 95% CI: 0.17 to 0.55, P<0.01). The rs313152 polymorphism was associated with a low risk for BSS (aOR=0.51, 95% CI: 0.33 to 0.79, P<0.01), but not for non-BSS (aOR=1.22, 95% CI: 0.81 to 1.85, P<0.05). Furthermore, the interaction effect of the rs5938 and rs313152 polymorphisms for BSS of CHD was significantly based on an aOR value associated with the combination of the rs5938 GT genotype with the rs313152 TC genotype of 0.27 (95% CI: 0.1 to 0.7, P<0.01).

Conclusion

The PAFR gene rs5938 or rs313152 polymorphisms might be a potential biomarker for susceptibility to CHD, especially to BSS of CHD in Chinese Han population.

     

Chinese Herbal Medicine Xingnaojing Injection (醒脑静注射液) for Hypoxic Ischemic Encephalopathy in Newborns: A Systematic Review and Meta-Analysis

Objectives: To evaluate the efficacy and safety of Chinese herbal medicine Xingnaojing Injection(醒脑静注射液) for newborns with hypoxic ischemic encephalopathy(HIE). Methods: Literature was identified by searching the Pub Med, EMBASE, Cochrane Library, Cochrane Central, and four Chinese literature databases from the establishment of database to October in 2013. Relevant reference lists were also screened. Two reviewers independently evaluated the methodological quality of included studies. We also conducted the meta-analysis. Results: Thirteen trials involving 1,169 patients were included. There was no trial reported death or disability at the end of follow-up period. Meta-analysis of 4 trials(n=371) showed that there was no significant difference in the reduction of mortality [risk ratios(RR)=0.48, 95% confidence intervals(CI, 0.21, 1.13), P=0.09] between the Xingnaojing and control groups. Meta-analysis of 5 trials(n=359) showed that there was significant difference in reducing the major neurodevelopmental disability [RR=0.36, 95% CI(0.19, 0.66), P=0.001]. Meta-analysis of 6 trials(n=447) showed that there was a significant difference in the author self-defined symptom improvement [RR=1.25, 95% CI(1.14, 1.37), P0.01]. No fatal side-effects were reported. Conclusion: Based on the limited evidence, the routine use of Xingnaojing Injection for treatment of HIE in newborns is not recommended. Further well-conducted trials are justified.     

Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008

Introduction

Poor adherence reduces the potential benefits of osteoporosis therapy, lowering gains in bone mineral density resulting in increased risk of fractures.

Aim

To compare prescribing and adherence patterns of anti-osteoporotic medications in patients admitted to an urban teaching hospital in Ireland with a fragility type fracture to patients admitted to a rural hospital in the North Western region.

Methodology

We identified all patients >55 years admitted to Sligo General Hospital between 2005 and 2008 with a fragility fracture (N = 744) using the hospital in-patient enquiry system (HIPE). The medical card number of those patients eligible for the primary care reimbursement services scheme (PCRS) facilitated the linkage of the HSE-PCRS scheme database to the HIPE database which enabled a study to identify persistence rates of patients prescribed osteoporosis therapy after discharge. The results were compared to the findings of a similar study carried out in St. James’s Hospital, Dublin.

Results

The 12 months post-fracture prescribing increased from 11.0 % (95 % CI 9.6, 12.4) in 2005 to 47 % (95 % CI 43.6, 50.3) in 2008 in the urban setting and from 25 % (95 % CI 21.5, 28.9) to 39 % (95 % CI 34.5, 42.7) in the rural setting. Adherence levels to osteoporosis medications at 12 months post-initiation of therapy was <50 % in both study groups. Patients on less frequent dosing regimes were better adherers.

Conclusion

The proportion of patients being discharged on anti-osteoporosis medications post-fragility fracture increased between 2005 and 2008 in both patient groups. Sub-optimal adherence levels to osteoporosis medications continue to be a major concern.     

益气养阴活血中药对原发性干燥综合症患者外周血Th1/Th2免疫平衡的作用

Objective: To observe the effect of Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood on the expression of interferon-γ (IFN-γ)/interleukin-4 (IL-4) in peripheral blood and disease activity in primary Sjogren''s syndrome (pSS) patients, and to study the relationship between the immune balance of Th1/Th2 and the disease activity. Methods: A total of 66 pSS patients were randomized with tossing coins method into two groups: the integrative therapy group (34 cases) and the control group (32 cases); and 28 healthy subjects were taken as the normal group. The integrative therapy group was treated by Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood combined with hydroxychloroquine sulfate tablets and the control group was treated with hydroxychloroquine sulfate tablets. The treatment course was 3 months for both groups. The levels of serum immunoglobulin G (IgG), erythrocyte sedimentation rate (ESR), IFN-γ and IL-4 in peripheral blood were measured before and after treatment. Results: Compared with the normal group, the levels of IgG, ESR, IFN-γ and IL-4 were signi?cantly increased in pSS patients (P<0.05). Remarkably, after 3 months of treatment, these levels were dramatically decreased in both the integrative therapy group and the control group, although still higher than the normal group. The levels of IgG, ESR, IFN-γ and IL-4 in the integrative therapy group were lower than the control group and the same group before treatment (P<0.05). The ratio of IFN-γ/IL-4 also signi?cantly decreased after treatment. Moreover, the level of IFN-γ and the ratio of IFN-γ/IL-4 in the integrative theraphy group were signi?cantly lower than the control group (P<0.05). For all patients the ratio of IFN-γ/IL-4 before and after treatment was positive correlated with the levels of IgG and ESR. Conclusion: Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood can alleviate the disease activity of pSS by regulating the immune balance of Th1/Th2.